Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep 1;14(17):5610-8.
doi: 10.1158/1078-0432.CCR-08-0116.

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

Franz O Smith  1 , Stephanie G Downey, Jacob A Klapper, James C Yang, Richard M Sherry, Richard E Royal, Udai S Kammula, Marybeth S Hughes, Nicholas P Restifo, Catherine L Levy, Donald E White, Seth M Steinberg, Steven A Rosenberg
Affiliations

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

Franz O Smith et al. Clin Cancer Res. .

Abstract

Purpose: To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic melanoma treated with high-dose bolus i.v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines.

Study design: 684 consecutive patients with metastatic melanoma received high-dose bolus i.v. IL-2 either alone or in conjunction with a variety of melanoma vaccines. Treatments occurred between August 1, 1985 and January 1, 2006.

Results: The overall objective response rate was 13% for patients receiving IL-2 alone and 16% for patients who received IL-2 with vaccine. In patients treated with IL-2 alone (n=305) and IL-2 with vaccine (n=379), having an objective response was associated with survival beyond 4 years (P<0.0001). No pretreatment factors could be identified that were strongly associated with increased rate of objective response or long-term survival in patients receiving IL-2 alone. In patients receiving IL-2 with vaccines, there were increased response rates in patients with s.c. or cutaneous disease only and lower response rates with visceral disease only. Patients who received the gp100:209-217(210M) peptide plus IL-2 showed a strong trend to increased objective responses compared with IL-2 alone (22% versus 12.8%; P=0.01) and also compared with patients who received a variety of vaccines that did not include this immunogenic peptide (13.8%; P=0.009).

Conclusion: IL-2 can produce a modest response rate in patients with metastatic melanoma including patients with durable complete responses. S.c. or cutaneous disease only and vaccination with gp100:209-217(210M) peptide was associated with significant increase in response rates.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve of overall survival for all patients treated with IL-2 alone.
Fig. 2
Fig. 2
Kaplan-Meier curve of overall survival for all responding patients treated with IL-2 alone.
Fig. 3
Fig. 3
Kaplan-Meier curve of overall survival for all patients treated with IL-2 with vaccine.
Fig. 4
Fig. 4
Kaplan-Meier curve of over all survival of responding patients treated with IL-2 with vaccine.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
    1. Balch CM, Atkins MB, Sober AJ. Cutaneous melanoma. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer. Principles & practice of oncology. 7. Philadelphia: Lippincott-Raven Publishers; 2005. p. 1754.
    1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16. - PubMed
    1. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907–13. - PubMed
    1. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003;9:2973–80. - PMC - PubMed

MeSH terms